Search
Highlights of Past EHA (HOPE) Middle East and North Africa (MENA) 2021 - report
The sixth HOPE MENA, with highlights of the EHA Annual Congress, successfully concluded September 23-24. Fully virtual for the second year in a row, the program was compiled together with eight regional partner societies.
Read morePublications
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network
Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott…
Young EHA Committee
Current committee members
Nuno Borges, United Kingdom (Chair)
Alba Maiques Diaz, Spain (Vice-Chair)
Elizabeth Macintyre, France (EHA Past President)
Regular members
Franziska Auer, USA/Germany
Anna Avagyan, Armenia
Côme Bommier, France
Lorenzo Brunetti, Italy
Eleni Gavriilaki, Greece
Ruxandra Irimia, Romania
Rafal Machowicz, Poland
Pedro Moura, Sweden
Rhiannon Newman, Finland
Marlies Vanden Bempt, Belgium
Carlo Zaninetti, Germany
AimYoung…
Meeting report | HOPE LA 2019 | Mendoza, Argentina
The first edition of the Highlights of Past EHA (HOPE) meeting in Latin America (LA) was held on October 4-5, 2019 in Mendoza, Argentina.
Read morePrivacy statement
May 21, 2021
Privacy Statement European Hematology Association
Personal Data is processed in the context of the services provided by European Hematology Association (hereinafter also; “EHA”).
Can Eltrombopag help children with ITP say goodbye to bleeding?
Immune thrombocytopenia (ITP) is a rare disease in children, affecting 5 in 100,000. Most children get better quickly without intervention but up to 30% will still have disease at 12 months.
Late-Breaking Abstract Submission
Late-breaking abstract procedureThe official late-breaking abstract submission will open from May 2 to 9, 2025 (09:00 CEST). The full late-breaking abstract submission terms & conditions can be found here.
Read morePresentations
EHA-ISHBT Hematology Tutorial
Session 1: Congenital and acquired neutropenias and bone marrow failure
Lecture: F Fioredda (here)
Clinical case: F Fioredda (here)
Self-assessment cases:
Speaker 1: M Mahapatra (Permission not granted)
Speaker 2: A Khurana (here)
Session 2: Hemolytic Anemia
Lecture: L Da Costa (Not available)
Clinical case: L…
TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS
Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- »